



PHAARMASIA

Phaarmasia Ltd.

16, Phase III, IDA, Jeedimetla, Hyderabad - 500 055. INDIA.

Tel : 91-40-23095002 / 23095690, Fax : 91-40-23097323

E-mail : phaarmasia@gmail.com, www.phaarmasia.in

CIN : L24239TG1981PLC002915

Date: 10.02.2022

To
The General Manager,
Listing Department,
BSE Limited,
1st Floor, New Trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street Fort,
Mumbai-400001

Dear Sir/Ma'am,

Sub: Financial Results for the quarter ended 31st December, 2021 – Regulation 33(3)(a) of SEBI (LODR) Regulations, 2015

Ref: Company Scrip Code: 523620

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at their meeting held on Thursday, 10th February, 2022 at 04:00 P.M., interalia, considered and approved the Financial Results for the quarter ended 31st December, 2021.

A copy of Financial Results for the quarter ended 31st December, 2021, along with copy of Auditor's Limited Review Report is enclosed herewith.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,
for **Phaarmasia Limited**

Urvashi Bhatia
Company Secretary & Compliance Officer

Pharmasia Limited

Regd. Office: Plot No.16 Phase III, I.D.A. Jeedimetla, Hyderabad - 500 055, Telangana
(CIN: L24239TG1981PLC002915)

Website:pharmasia.in, Email: Pharmasia@gmail.com, Phone No.040-23095002

Un-Audited Financial Results for the Quarter and Nine Months Ended 31st, December 2021


S No	Particulars	Quarter Ended			Nine Months Ended		Rs. In Lakhs
		December 31st 2021	September 30th 2021	December 31st 2020	December 31st 2021	December 31st 2020	March 31st, 2021
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Income						
	a) Revenue from Operations	387.26	529.00	481.64	1305.23	1453.12	1989.53
	Total Revenue from operations	387.26	529.00	481.64	1305.23	1453.12	1989.53
	b) Other Income	8.14	15.86	61.41	31.55	76.80	89.35
	Total Income	395.40	544.87	543.05	1336.78	1529.92	2078.88
2	Expenses						
	a) Cost of materials Consumed	387.69	380.49	377.91	1144.02	957.33	1248.94
	b) Changes in inventories	-21.79	95.40	15.80	-33.52	120.20	208.89
	c) Employee benefits expense	29.11	30.88	34.53	92.05	108.69	149.52
	d) Finance costs	0.14	0.07	0.16	0.35	0.67	1.17
	e) Depreciation and amortization expense	7.37	7.37	8.58	22.04	25.64	34.12
	f) Other expenses	66.91	102.93	101.96	252.74	295.54	388.37
	Total Expenses (a to f)	469.44	617.14	538.94	1477.68	1508.07	2031.02
3	Profit before tax (1-2)	-74.04	-72.28	4.11	-140.90	21.85	47.87
4	Tax expenses						
	- Income Tax	0.00	-1.73	2.04	0.00	6.87	18.47
	- Deferred Tax	-1.23	0.45	-0.47	-1.15	-1.36	-1.80
5	Net Profit for the period (3-4)	-72.80	-70.99	2.54	-139.75	16.34	31.19
6	Other comprehensive income						
	a) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	-9.06
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	2.28
	b) (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	0.00	0.00	0.00	0.00	-6.78
7	Total Comprehensive income (5 +6)	-72.80	-70.99	2.54	-139.75	16.34	24.42
8	Paid-up Equity Share Capital (Rs.10/- per Equity Share)	682.70	682.70	682.70	682.70	682.70	682.70
9	Other Equity						682.58
10	Earnings per share (Face Value of Rs.10/- each)						
	(a) Basic (In Rs.)	-1.07	-1.04	0.04	-2.05	0.24	0.46
	(b) Diluted (In Rs.)	-1.07	-1.04	0.04	-2.05	0.24	0.46

- These financial results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter.
- The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 10-02-2022.
- The Financial results are subject to the Limited Review carried out by the statutory auditor's as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015.
- The entire operations of the Company relate to only one segment . Hence, segmental reporting as per IND AS-108 is not made.
- The full format of the Quarterly un audited Financial Results are available on company's website at pharmasia.in and the stock exchange's website www.bseindia.com.
- Estimation uncertainty relating to the global health pandemic on COVID-19
The management has considered the possible effects, if any, that may result from the pandemic relating to COVID - 19 on the carrying amounts of trade receivables & inventories. In assessing the recoverability of receivables, the Company has considered internal and external information upto the date of approval of these financial results including credit reports and economic forecasts. The Company has performed sensitivity analysis on the assumptions used and based on current indicators of future economic conditions, the Company expects to recover the carrying amount of these assets. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes and future economic conditions.

Place: Hyderabad
Date: 10-02-2022

By and on behalf of the Board
for Pharmasia Limited

Y.N.Bhaswar Rao
Whole Time Director
DIN: 00019052



Pharmasia Limited

Regd. Office: Plot No.16 Phase III, I.D.A. Jeedimetla, Hyderabad - 500 055, Telangana
(CIN: L24239TG1981PLC002915)

Website: www.pharmasia.in, e-mail: pharmasia@gmail.com, Phone No.040-23095002

Extract of Un Audited Financial Results for the Quarter and nine months ended 31.12.2021


Sl. No.	Particulars	Quarter ended			Nine Months Ended		Rs. In Lakhs
		December 31st 2021	September 30th 2021	December 31st 2020	December 31st 2021	December 31st 2020	Year ended March 31st, 2021
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
1	Total income						
2	Net Profit (before Tax, Exceptional and/or Extraordinary items)	395.40	544.87	543.05	1336.78	1529.92	2078.88
3	Net Profit before tax (after Exceptional and/or Extraordinary items)	-74.04	-72.28	4.11	-140.90	21.85	47.87
4	Net Profit after tax (after Exceptional and/or Extraordinary items)	-74.04	-72.28	4.11	-140.90	21.85	47.87
5	Total Comprehensive Income [Comprising Profit after tax and Other Comprehensive Income (after tax)]	-72.80	-70.99	2.54	-139.75	16.34	31.19
6	Paid up Equity Share Capital (Rs.10/- Per Equity Share)	-72.80	-70.99	2.54	-139.75	16.34	24.42
7	Reserves (excluding Revaluation Reserve) as shown in the Balance Sheet of previous year ended	682.70	682.70	682.70	682.70	682.70	682.70
8	Earnings Per Share (of Rs.10/- each) (Not Annualised):						682.58
	a) Basic	-1.07	-1.04	0.04	-2.05	0.24	0.46
	b) Diluted	-1.07	-1.04	0.04	-2.05	0.24	0.46

The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 10-02-2022.

Note : The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulations 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Un Audited Financial Results are available on company's website at pharmasia.in and the stock exchange's website www.bseindia.com.

By and on behalf of the Board
for Pharmasia Limited

Y.N.Bhaskar Rao
Whole Time Director
DIN: 000190524



Place : Hyderabad
Date 10-02-2022



SATHULURI & CO. CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Financial Results of Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
PHAARMASIA LIMITED

We have reviewed the accompanying statement of unaudited financial results of **PHAARMASIA LIMITED** ('The Company') for the quarter ended 31st December, 2021. This statement is the responsibility of the company's management and has been approved by the board of directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements..

For Sathuluri & Co.,
Chartered Accountants
Firm Reg No.006383S

(S.S. Prakash)
Partner

Membership No.202710



UDIN : 22202710ABEATE6297

Place: Hyderabad

Date: 10/02/2022